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rabian JAbstract Naproxen (C14H14O3) is a non-steroidal anti-inﬂammatory drug (NSAID). It is impor-
tant to investigate its structure to know the active groups and weak bonds responsible for medical
activity. In the present study, naproxen was investigated by mass spectrometry (MS), thermal anal-
ysis (TA) measurements (TG/DTG and DTA) and conﬁrmed by semi empirical molecular orbital
(MO) calculation, using PM3 procedure. These calculations included, bond length, bond order,
bond strain, partial charge distribution, ionization energy and heat of formation (DHf). The mass
spectra and thermal analysis fragmentation pathways were proposed and compared to select the
most suitable scheme representing the correct fragmentation pathway of the drug in both tech-
niques. The PM3 procedure reveals that the primary cleavage site of the charged molecule is the
rupture of the COOH group (lowest bond order and high strain) which followed by CH3 loss of
the methoxy group. Thermal analysis of the neutral drug reveals a high response to the temperature
variation with very fast rate. It decomposed in several sequential steps in the temperature range 80–
400 C. These mass losses appear as two endothermic and one exothermic peaks which required
energy values of 255.42, 10.67 and 371.49 J g1 respectively. The initial thermal ruptures are similar
to that obtained by mass spectral fragmentation (COOH rupture). It was followed by the loss of the
methyl group and ﬁnally by ethylene loss. Therefore, comparison between MS and TA helps in
selection of the proper pathway representing its fragmentation. This comparison is successfully con-
ﬁrmed by MO-calculation.
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Naproxen (NAP) has an IUPAC name, 2-Naphthaleneacetic
acid, 6-methoxy-a-methyl-, (s)-(+)-(s)-6-methoxy-a-methyl-2-
naphthaleneacetic acid (States Pharmacopoeia, 2004; Haqueing Saud University.
xen drug using mass spectrometry, thermal analyses and semi-empirical
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2 M.A. Zayed et al.et al., 2010) and a general formula (C14H14O3). It belongs to a
group of drugs called nonsteroidal anti-inﬂammatory drugs
(NSAIDs). It works by reducing hormones that cause inﬂam-
mation and pain in the body. Naproxen is used to treat pain or
inﬂammation caused by conditions such as arthritis, ankylos-
ing spondylitis, tendinitis, bursitis, gout, or menstrual cramps
(Mura et al., 2002; Kosaka et al., 1994; Larsen and Mc Ewen,
1998).
Mass spectrometry (MS) is one of the most powerful
analytical techniques, particularly for pharmaceutical analy-
sis, where good selectivity and high sensitivity are often
needed. In the pharmaceutical industry measurements of
drugs and their metabolites in plasma are essential for drug
discovery and development. The more accurate and rapid
measurements, is the more quickly a drug can progress to-
ward regulatory approval. Time-of-ﬂight mass spectrometer
(TOF-MS) delivers high sensitivity, resolution, and exact
mass measurements. A variety of ion source and software
options makes MS a versatile choice for a range of analyt-
ical challenges (Karatasso et al., 2007; Jayasimhulu et al.,
2006; Han et al., 2006; Delong et al., 2001; Koivusalo
et al., 2001).
Thermal analysis techniques can provide important infor-
mation regarding storage and stability of pharmaceuticals.
Thermal analysis methods have thus become important tools
for the development of modern medicines (Kulp et al., 2004;
Barbas et al., 2007; Sovizi, 2010; Picker-Freyer, 2007; Santos
et al., 2008). These are precise and accurate techniques with
low sample requirements, and can provide detailed informa-
tion about new chemical entities even at the very earliest
stages of discovery and development of the new composi-
tions and drugs (Michalik et al., 2008; Cooks et al., 1973;
Lever and Papadaki, 2004; Levsen, 1978). Thermogravimet-
ric TG/DTG analysis is used to provide quantitative infor-
mation on weight losses due to decomposition and/or
evaporation of low molecular materials as a function of time
and temperature. In conjunction with mass spectrometric
analysis (Bourcier and Hoppiliard, 2003; Fahmey et al.,
2001; Zayed et al., 2010, 2012a), the nature of the released
volatilize may be deduced, thus greatly facilitating the inter-
pretation of thermal degradation processes. On the other
hand, computational quantum chemistry can provide addi-
tional information about the atoms and bonds, which can
be used successfully in an interpretation of experimental re-
sults (Somogyi et al., 1991). Application of computational
quantum chemistry in addition to experimental results (MS
and TA) gives valuable information about the atoms and
bonds which helps in the description and prediction of pri-
mary fragmentation site of drug cleavage and the subsequent
one (Zayed et al., 2005, 2006, 2007, 2012b).
The aim of the present work is focusing on further appli-
cation of our previous work (Zayed et al., 2005, 2006, 2007,
2012b) in the case of naproxen drug. This work includes a
correlation between, mass spectral fragmentation and ther-
mal analysis degradation of the drug and comparing these
experimental data with the theoretical molecular orbital
(MO) calculation to identify the weakest bonds ruptured
during both mass and thermal studies. Consequently the
choice of the correct pathway of such fragmentation know-
ing this structural session of bonds can be used to decide the
active sites of the drug responsible for its chemical, biologi-
cal and medical reactivity.Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://2. Experimental
2.1. Materials
All chemicals used were of analytical reagent grade (AR), and
of highest purity available. They included naproxen (NAP,
M.wt = 230.26 g mole), as an authentic sample which was
kindly supplied by the Egyptian Drug Control Authority
(EDCA), Cairo (Egypt).
2.2. Mass spectrometry (MS)
Electron ionization (EI) mass spectrum of naproxen is ob-
tained using Thermo Finnegan TRACE DSQ quadruple mass
spectrometer with electron multiplier detector equipped with
GC–MS data system at the Cairo University micro-analytical
center. The direct probe (DP) for solid material was used in
this study. The sample was put into a glass micro vial, by a
needle (1 lg max), the vial was installed on the tip of the
DP containing heating cable and inserted into the evacuated
ion source. The sample was ionized by an electron beam emit-
ted from the ﬁlament, the generated ions being effectively
introduced into the analyzer by the focusing and extractor
lenses system. The MS was continuously scanned and the ob-
tained spectra were stored. Electron ionization mass spectra
were obtained at ionizing energy value of 70 and 12 eV, ioniza-
tion current of 60 lA and vacuum is better than 106 torr.
2.3. Thermal analyses (TA)
The thermal analyses of naproxen drug were performed using
conventional thermal analyzer (Shimadzu system of DTA-50
and 30 series TG-50) at the Cairo University micro-analytical
center. The mass losses of 5 mg sample and heat response of
the change of the sample were measured from room tempera-
ture up to 600 C. The heating rate, in an inert argon atmo-
sphere, was selected as 10 C min–1. These instruments were
calibrated using an indium metal as a thermal stable material.
The reproducibility of the instrument reading was determined
by repeating each experiment more than twice.
2.4. Computational method
The MO calculations were performed using semi-empirical
molecular orbital calculation. The method used in these com-
putations is the parametric method (PM3) described by Stewart
(1989). The default criteria for terminating all optimizations
were increased by a factor of 100 (keyword PRECISE). Vibra-
tional frequencies were computed for the studied structures
(keyword FORCE) so as to check whether the newly designed
geometries are local minima. All the molecular orbital calcula-
tions were carried out at the restricted Hartree–Fock level
(RHF) for the neutral molecule of naproxen while the unre-
stricted Hartree–Fock level (UHF) was carried out for its cat-
ion by using the PM3 method followed by full optimization
of all geometrical variables (bond lengths, bond angles, and
dihedral angles), without any symmetry constraint. All struc-
tures were optimized to a gradient norm 0.01–0.05, using the
eigenvector following the EF routine (Baker, 1986). All the
semi empirical MO calculations were performed with thexen drug using mass spectrometry, thermal analyses and semi-empirical
dx.doi.org/10.1016/j.arabjc.2013.09.025
Figure 1 The geometrical structure of Naproxen and its num-
bering system.
Investigation of naproxen drug using mass spectrometry, thermal analyses and semi-empirical molecular 3MOPAC2000 software package (Stewart, 1999) implemented
on an Intel Pentium IV 3.0 G Hz computer.
3. Results and discussion
It is of great interest to study the chemistry and reactivity of
naproxen drug because of its importance in medicine. TheFigure 2 Thermal analyses of standard
Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://geometrical structure of NAP and its numbering system is
shown in Fig. 1.
Knowledge obtained from thermal decomposition mecha-
nisms of the neutral drug is very important to understand
the chemical process that is shared in biological systems. It is
difﬁcult to establish the exact major fragmentation pathway
in EI using conventional MS. With combining the above two
techniques and the data obtained from the MO calculation,
it is possible to understand the following topics:
1. Stability of the drug under thermal degradation in solid
state and mass spectral fragmentation in gas phase.
2. Prediction of the primary site of fragmentation and subse-
quent bond cleavage.
3. The correct pathway in both techniques.
4. Understanding what actually happened in biodegradation
of the drug or its derivatives in vivo system and metabolites.
5. Thermal stability of the drug was a required information
for handling, strength and shelf life.NAP drug: (a) TG/DT and (b) DTA.
xen drug using mass spectrometry, thermal analyses and semi-empirical
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4 M.A. Zayed et al.3.1. Thermal analysis
The TA data of naproxen (NP) are illustrated in Fig. 2a and b.
It is clear from TG/DTG curves (Fig. 2a) that, this compound
decomposed completely within the temperature range of 80–
480 C (mass loss = 99.0%). The main mass loss of this com-
pound occurs at 266.93 C as shown by DTG curve (Fig. 2a).
From DTA curve (Fig. 2b) it is clear that thermal decomposi-
tion of NAP occurs in two main endothermic regions and one
exothermic region: 150–170, 210–280 and 400–480 C which
cannot easily be described by TG technique. These endother-
mic and exothermic mass losses required energy values of
255.41, 10.67 and 371.45 kJ mol1 at 157.0, 270.0 and
452.0 C respectively. Therefore, the proposed thermal decom-
position of NAP can be carried out in three consecutive steps
as shown in Scheme 1.
3.2. Mass spectral (MS) fragmentation of Naproxen drug
The electron ionization (EI) mass spectrum for NAP drug mea-
sured at 70 and 12 eV was recorded (Fig. 3a and b) and inves-
tigated. The spectrum of NAP drug at 70 eV (Fig. 3a) is
characterized by many competitive and consecutive pathways,
thus forming many intense fragment ions (Scheme 2). The main
fragmentation pathways for NAP after ionization of neutral
molecule at 8.764 eV consist of three principal pathways (path
1–3) as rationalized in Scheme 2. The signal that appears atH3CO
C
H
CH3
COOH
C14H14O3
mol mass=230
-CO
mass los
at 150-1
Scheme 1 The proposed thermal
Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://m/z= 230 (RI = 100%) refers to the appearance of the main
molecular ion [C14H14O3]
+. The high intensity reﬂects the sta-
bility of the molecular ion of NAP. The fragment ion at signal
m/z= 185 (Scheme 2, path 1) represents the second most
prominent ion [C13H13O]
+ (RI = 90.42%) and is mainly due
to the rupture of COOH molecule from main molecular ion.
Also, its high stability is due to the presence of the lone pairs
of electrons of oxygen atom with two aromatic rings. Two
important fragment ions are observed in the mass spectra at
m/z= 170 (RI = 26.65%) and at m/z= 154 (RI = 12.85%).
These fragment ions may be due to the rupture of CH3 and
OCH3 radicals, respectively. The fragment ion observed at
m/z= 139 may be due to the formation of [C11H7]
+. Compar-
ison of TA (Scheme 1) and MS path 1 (Scheme 2) refers to the
coincidence between TA scheme and MS of NAP drug metab-
olites (vitro fragments).
At the low energy value of 12 eV (Fig. 3b), the base peak is
observed at molecular ion m/z= 230, IR = 100%. It is noted
that the peaks corresponding to the secondary process
(m/z= 185) were observed at RI < 10%. Comparison of the
data in Fig. 3a to that in Fig. 3b, refers to the fact that 70 eV
is sufﬁcient energy for fragmentation of NAP (mole mass 230)
to give its daughter fragment ion [C13H13O]
+ (m/z= 185,
RI = 90.42%), but 12 eV the lower energy is insufﬁcient to give
this fragment from its parent drug molecule. This also conﬁrms
the proposed mass Scheme 2, which indicates that the path 1 is
the only possible way to form [C13H13O]
+ at 70 eV. This is also
conﬁrmed by the full scan MS/MS spectrum (Fig. 4) (da-fang2 (44)
s=19.13%
70 oC
CH2
CH3
H3CO
C13H14O
mol mass=186
C11H9O
mol mass=157
-OCH3 (31)
mass loss=13.48%
at 400-480 oC
C10H6
mol mass=126
-C2H5(29)
mass loss=12.61%
210 - 280 oC
H3CO
decomposition pathway of NA.
xen drug using mass spectrometry, thermal analyses and semi-empirical
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Figure 3 Mass spectrum of NAP at: (a) 70 eV and (b) 12 eV.
Investigation of naproxen drug using mass spectrometry, thermal analyses and semi-empirical molecular 5et al., 2003) ofNAP that showed amolecular ion atm/z= 229.1
of very low intensity, whereas its daughter fragment ion
[C13H13O]
+ (m/z= 184.9, RI = 100%) appeared as base peak.
3.3. Computational molecular orbital (MO) calculation
Molecular orbital (MO) calculation gives valuable informa-
tion about the structure and reactivity of the molecules,
which actually are used to support the experimental evi-
dences (Fahmey et al., 2001; Zayed et al., 2005, 2006,
2007, 2010, 2012a,b). The most important parameters calcu-
lated using MO calculation includes bond orders, bond
length, charge distribution, bond strain, and heat of forma-
tion and ionization energy. In the present work, the calcula-
tions have been carried out on NAP neutral molecule
(related to TA decomposition) and charged molecular ion
(related to MS fragmentation) which is used for prediction
of weakest bond rupture to follow the fragmentation path-
ways in both techniques.
Fig. 1 shows the numbering system of NAP skeleton that
helps in ordering the calculated parameters Table 1 presents
the values of bond length (A˚), bond order and bond strain
(kcal mol1) of NAP drug in both neutral and in cationic
forms. One can conclude the following from Table 1:Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://1. Small differences in bond length in NAP system upon
ionization indicate that no appreciable change in the
geometries upon ionization.
2. The lowest bond order (important for prediction of pri-
mary site of cleavage) observed at bond C17–C21 for
both neutral (0.919) and positive species (0.932).
3. Upon ionization the stability of the molecule decreased
by 180.53 kcal mol1 (DHf (97.79)  DHþf (92.74)).
The charge distribution on different atoms (C and O) and
heats of formation; DHf (kcal mol
1) for neutral and charged
NAP species are summarized in Fig. 5. Signiﬁcant changes in
the electron distribution with given system often takes place
during the ionization.
3.4. Correlation between thermal analysis (TA) decomposition
and MO-calculation
As indicated, the determination of initial bond rupture would
be an important ﬁrst step in using this calculation in predica-
tive manner. MO calculation and PM3 procedure revealed that
the C17-C12 bond has the lowest bond order at 0.919 and large
bond length = 1.521 A˚ and bond strain = 0.032 kcal mol1.
Experimental TA curves (Fig. 2) of naproxen reveal that thexen drug using mass spectrometry, thermal analyses and semi-empirical
dx.doi.org/10.1016/j.arabjc.2013.09.025
Scheme 2 Proposed mass fragmentation of NAP drug in cationic form at 70 eV.
Figure 4 Full scan MS/MS spectrum of m/z= 230 of NAP
(Aresta et al., 2006).
6 M.A. Zayed et al.ﬁrst weight loss equals to 19.56%. This weight loss corre-
sponds to the rupture of COOH (lowest bond order) at tem-
perature 157 C of range 150–170 C, followed by the
rupture of C3–O13 bond (bond order = 1.037, bond
length = 1.364 A˚, bond strain = 0.032 kcal mol1). The sec-
ond weight loss of 13.65% occurs at temperature in the range
180–280 C. This weight loss is mainly due to rupture of OCH3Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://(O + CH3). This wide range of temperature may be due to
slow fragmentation with small half life time (Pourmortazavi
et al., 2008), since in TA decomposition of the molecules is
continuously energized and determined by gas evolution and
the distribution of energy can be described by energy (Hosseini
et al., 2005).
On the other hand, the electrostatic repulsion between C17
(0.012) and C21 (0.386) for neutral molecule facilitates the
rupture of this bond (C17–C12), than the second rupture of C3
(0.100) and O13 (0.187) atoms, indicating that the COOH
loss is more easy than O–CH3 loss.
3.5. Correlation between mass spectral (MS) fragmentation and
MO calculations of charged molecule
The scope of this investigation is restricted to a search for predic-
tion of the ﬁrst and subsequent bond ruptures during the course
of fragmentation ofNAPdrug inMS technique. The subsequent
fragmentation inMS is determined to a large extent by the initial
bond rupture ofmolecular ion (Zayed et al., 2007; Stewart, 1989,
1999; Baker, 1986). A number of mass spectrometric techniques
have utilized helping in rationalized the correct pathways of thexen drug using mass spectrometry, thermal analyses and semi-empirical
dx.doi.org/10.1016/j.arabjc.2013.09.025
Table 1 Comparison between computed bond length (in A˚), bond order and bond strain (kcal mol1) using the PM3 method for
neutral and molecular cation of NAP drug.
Bond Bond length (A˚) Bond order Bond strain (kcal mol1)
Neutral Cation Neutral Cation Neutral Cation
C1–C2 1.365 1.396 1.634 1.639 0.008 0.009
C2–C3 1.428 1.397 1.197 1.215 0.014 0.013
C3–C4 1.377 1.400 1.548 1.223 0.037 0.036
C4–C5 1.420 1.399 1.218 1.437 0.026 0.024
C5–C6 1.409 1.398 1.334 1.190 0.018 0.017
C6–C1 1.424 1.397 1.201 1.130 0.015 0.013
C6–C7 1.418 1.398 1.232 1.444 0.021 0.018
C7–C8 1.375 1.398 1.577 1.305 0.025 0.020
C8–C9 1.419 1.398 1.241 1.331 0.025 0.020
C9–C10 1.368 1.396 1.607 1.545 0.008 0.009
C10–C5 1.421 1.398 1.220 1.165 0.019 0.021
C3–O13 1.379 1.364 1.037 1.207 0.032 0.032
C8–C17 1.504 1.513 0.973 0.995 0.089 0.083
O13–C19 1.406 1.405 0.985 0.958 0.006 0.005
C17–C20 1.522 1.535 0.983 0.966 0.052 0.043
C17–C21 1.521 1.520 0.919 0.932 0.032 0.037
C21–O22 1.218 1.209 1.807 1.778 0.001 0.001
C21–O23 1.354 1.342 1.053 1.105 0.005 0.005
Dipole moment (Debye) Electron aﬃnity (eV) Heat of formation (kcal mol1) Ionization potential (eV)
(a) 2.44 0.526 97.78709 8.764
(b) 5.96 4.982 92.74 12.999
(a) Neutral form values and (b) cationic form values.
The order of the bond strength: C21–O22 > C1–C2 > C9–C10 > C7–C8 > C3–C4 > C5–C6 > C8–C9 > C6–C7 > C10–C5 > C4–
C4 > C6–C1 > C2–C3 > C21–CO23 > C3–O13 > O13–C19 > C17–C20 > C8–C17 > C17–C21.
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Figure 5 Charge distribution on different atoms for NAP: (a)
neutral molecule and (b) molecular cation.
Investigation of naproxen drug using mass spectrometry, thermal analyses and semi-empirical molecular 7molecules, among which are: threshold measurement and meta-
stable abundance ratios (Cooks et al., 1973). On the other hand,
computational process can provide important information
which can be used successfully in description of primary site of
cleavage. The theoretical data obtained can be considered valu-Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
molecular orbital calculation. Arabian Journal of Chemistry (2013), http://able for MS; because they were studied in gas phase species,
which can be handled much more easily by quantum chemistry
(Stewart, 1989, 1999; Baker, 1986). Mass spectrum of NAP re-
veals (Scheme 2) three competitive and consecutive fragmenta-
tion pathways.
PM3 procedure on cationic form (Table 1) reveals that the
C17–C21 bond is the ﬁrst site of bond cleavage (lowest bond or-
der = 0.932, large bond length = 1.520 A˚, bond strain =
0.037 kcal mol1). This bond cleavage accompanied by rupture
of COOH molecule forms the fragment ion [C13H13O]
+ at
m/z= 185 and relative intensity = 90.42%. Further loss is a
rupture of CH3 molecule from this fragment at m/z= 170
[C12H10O]
+ (Scheme 2, path 1). On the other hand, the electro-
static repulsion between the charge localized on C17 (0.057)
and C21 (0.392) atom (Fig. 5) facilitates the loss of COOH
molecule.
The MO calculation data of fragment ion [C13H13O]
+ at
m/z=185 are shown in Table 2. These data refer to the ordering of
its bond strength; which is given by C9–C10>C1–C2>C3–C4
>C8–C17>C7–C8>C6–C7>C4–C5>C2–C3>C5–C6>
C6–C1>C10–C5>C8–C9>C3–O13>C17–C20>O13–C19.
Thismeans that, the ﬁrst rupturedbond isO13–C19 leading to the for-
mation of fragment ion m/z=170 [C12H10O]
+ via the loss of CH3
group. It was followed by the rupture of the bond C17–C20; which
leads to the formation of m/z=154 (RI= 12.85%) via the loss of
CH3Oandﬁnally to theruptureof thebondC3–O13 leadingto the for-
mation of fragment ion [C11H7]
+ that observed at m/z=139. This
means that all fragment ions are coming from the daughter
m/z=185 not from the parent drug m/z= 230. This is also is in
good agreement with the proposed thermal and mass schemes
(1 and 2) and MS/MS data (da-fang et al., 2003).xen drug using mass spectrometry, thermal analyses and semi-empirical
dx.doi.org/10.1016/j.arabjc.2013.09.025
Table 2 Comparison between computed bond length (in A˚) and bond order using the PM3 method for neutral and molecular cation
of [C13H13O]
+ at m/z= 185 system.
Bond Bond length (A˚) Bond order
Neutral Cation Neutral Cation
C1–C2 1.380 1.360 1.484 1.679
C2–C3 1.422 1.436 1.222 1.165
C3–C4 1.394 1.400 1.389 1.364
C4–C5 1.413 1.394 1.252 1.394
C5–C6 1.424 1.435 1.218 1.167
C6–C1 1.421 1.437 1.206 1.131
C6–C7 1.410 1.381 1.256 1.489
C7–C8 1.412 1.429 1.257 1.174
C8–C9 1.430 1.448 1.164 1.089
C9–C10 1.376 1.355 1.510 1.729
C10–C5 1.424 1.436 1.184 1.138
C3–O13 1.379 1.347 1.033 1.158
C8–C17 1.406 1.373 1.274 1.562
O13–C19 1.406 1.415 0.986 0.958
C17–C20 1.700 1.464 1.022 1.055
The order of the bond strength: C9–C10 > C1–C2 > C3–C4 > C8–C17 > C7–C8 > C6–C7 > C4–C5 > C2–C3 > C5–C6 > C6–
C1 > C10–C5 > C8–C9 > C3–O13 > C17–C20 > O13–C19.
8 M.A. Zayed et al.3.6. Correlation between TA and MS
It is important to make a discussion between results of TA and
MS of NAP, to see the behavior of the drug in both tech-
niques. This comparison shows the agreement between mass
path 1 and TA. In both TA and MS techniques, it is proved
that the C17–C21 bond is the ﬁrst site of rupture. In TA,
COOH rupture is followed by OCH3 (O + CH3) (Scheme 1).
In MS fragmentation it is initiated by COOH rupture and fol-
lowed by CH3 group rupture in path 1 (Scheme 2). The ob-
tained fragment ions in MS are m/z= 230, 185, 170, 154
and 139, that are conﬁrmed by TA. This can be considered
as a vitro metabolites of NAP drug; which are very similar
to vivo urinary metabolites of naproxen obtained by liquid
chromatography–electro-spray mass spectrometry (Aresta
et al., 2006).
4. Conclusion
The aim of this study is concerning with the applicability of
experimental TA and MS techniques and theoretical investiga-
tion MO calculations, using the PM3 procedure on NAP drug.
From correlation between MS and MO calculations, it is
clear that the C17–C21 bond is the ﬁrst site of bond cleavage.
This refers to lowest bond order, large bond length and less
bond strain. This bond cleavage accompanied by the rupture
of COOH molecule forming the fragment ion [C13H13O]
+ at
m/z= 185 and relative intensity = 90.42%. Further loss is a
rupture of CH3 molecule from this fragment at m/z= 170
[C12H10O]
+. On the other hand, the electrostatic repulsion be-
tween the charges localized on C17 and C21 atoms facilitates
the loss of COOH molecule. Therefore, this investigation con-
cluded that the correlation between both practical and
theoretical techniques helps in the selection of the proper
pathway representing the decomposition of this drug to give
its vitro metabolites.Please cite this article in press as: Zayed, M.A. et al., Investigation of napro
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group. MO calculations reveal that the C17–C12 bond has
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Also, the electrostatic repulsion between C17 and C21 for neu-
tral and cationic NAP forms facilitates the rupture of the bond
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